January 7, 2021
PAR-21-173 - Support for Research Excellence – First Independent Research (SuRE-First) Award (R16 - Clinical Trial Not Allowed)
National Institute of General Medical Sciences (NIGMS)
This Notice is to clarify the eligibility requirements of PAR-21-173 "Support for Research Excellence - First Independent Research (SuRE-First) Award (R16 - Clinical Trial Not Allowed)" described in Section III.1 Eligible Applicants, Eligible Organizations, which is in bold text below:
This funding opportunity announcement is open to all institutions of higher education that:
1) award undergraduate (B.S. or B.A.) and/or graduate degrees in biomedical sciences; and
2) at the time of the application, have received no more than $6 million dollars per year (total costs) from NIH Research Project Grants (RPGs) in each of the preceding two fiscal years, calculated using NIH RePORTER; and
3) enroll at least 25% of undergraduate students supported by Pell grants based on the most recent two years of data available from the Integrated Postsecondary Education Data System (IPEDS) database maintained by the National Center for Education Statistics, or are an accredited medical/health professional school with a historical mission statement that explicitly states that it was founded to educate students from nationally underrepresented backgrounds.
Clarification:
IPEDS reports the percentage of students supported by Pell grants in two ways: (1) the percentage of all undergraduates enrolled and (2) the percentage of full-time, first-time, degree/certificate-seeking undergraduate students. This Notice clarifies that institutions may use either option for determining their eligibility. No matter which category of IPEDS data is used, the institution’s Pell enrollment in that category must be at least 25% for the two most recent years of reported data.
Irina N. Krasnova, Ph.D.
National Institute of General Medical Sciences (NIGMS)
Email: irina.krasnova@nih.gov
and Human Services (HHS)
